Anatara Lifesciences (ASX:ANR) has provided an update on the recruitment progress for Stage 2 of its pivotal GaRP-IBS (Irritable Bowel Syndrome) trial following the recent changes to recruitment sites.
-
Latest News
MTPConnect cements US medtech links through MoU with Medical Alley
October 17, 2024 -
AusBiotech
More opportunities for connection during Australia's biggest week in biotech
October 17, 2024 -
Latest News
Neuren announces that trofinetide has received marketing authorisation in Canada
October 17, 2024
-
Latest News Anatara Lifesciences provides GaRP-IBS clinical trial update October 17, 2024
-
Latest News Nyrada says it has completed safety studies ahead of Phase 1 clinical trial October 17, 2024CEO James Bonnar said, "We are thrilled to have completed the GLP studies, which have confirmed a favourable safety profile for NYR-BI03, giving us confidence that it will transition well into human studies."
-
Latest News Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration October 17, 2024Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX) has announced a collaboration agreement between its subsidiary Osteopore International and NASDAQ-listed biopharmaceutical company CytoMed Therapeutics.
-
Latest News AusBiotech calling on experts to become mentors for Industry Growth Program October 15, 2024AusBiotech is seeking mentors to guide and support up-and-coming startups as they navigate the commercialisation pipeline.
-
AusBiotech AusBiotech releases 2023-2024 annual report October 15, 2024AusBiotech has announced the release of its 2024 Annual Report, showcasing a year of strong member engagement and sector enablement.
-
Latest News Immuron reports continued sales growth for Travelan October 15, 2024Immuron (ASX:IMC) has announced the continued strong sales growth of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract.
-
Latest News LTR Pharma says Spontan achieves faster absorption in completed pivotal study October 15, 2024LTR Pharma (ASX:LTP) has announced the successful completion of the pivotal clinical study for Spontan, the company’s novel intranasal formulation of vardenafil for the treatment of erectile dysfunction.
-
Latest News Respiri announces it has secured a major strategic investment October 15, 2024Respiri chairman Nicholas Smedley said, “The Board and I are pleased to welcome investors of this calibre onto our registry."
-
Latest News TGA approves new indication for Telix’s Illuccix to include patient selection for PSMA-targeted therapy October 10, 2024Telix has announced that the TGA has approved the use of Illuccix to select patients for PSMA-targeted radionuclide therapy.
-
AusBiotech Australia's premier life science investment event AusBioInvest 2024 October 10, 2024Australia's premier life science investment event, AusBioInvest 2024, kicks off on Tuesday, 29 October, in Melbourne.
-
Latest News Amplia Therapeutics CEO shares Prime Minister's Prize for Innovation October 10, 2024The CEO and managing director of Australian company Amplia Therapeutics (ASX:ATX), Dr Chris Burns, and Professor Andrew Wilks have shared the Prime Minister’s Prize for Innovation for their role in the discovery of JAK enzymes and their co-invention of the JAK inhibitor momelotinib.
-
Latest News Noxopharm contracts specialist manufacturer for SOF-SKN clinical trial October 10, 2024Noxopharm (ASX:NOX) has contracted a specialist supplier to manufacture SOF-SKN for the upcoming HERACLES clinical trial.
-
Latest News Firebrick Pharma announces the completion of share purchase plan October 10, 2024Firebrick Pharma (ASX:FRE) has announced the close of its Share Purchase Plan that was announced to the market on 12 September 2024.
-
AusBiotech Federal Minister for Health and Aged Care to speak at Australia’s biggest week in biotech October 8, 2024AusBiotech has announced Health Minister Mark Butler will join industry members, international delegates, and investors during Australia’s most significant week in biotechnology.
-
Latest News Chimeric says cancer patient achieves complete response in CHM CORE-NK trial October 8, 2024Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that a patient with Acute Myelogenous Leukemia has recorded a complete response in its Phase 1b CHM CORE-NK and Vactosertib combination.
-
Latest News Island Pharmaceuticals secures new funding to support key inflection points and pipeline build October 8, 2024Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has announced it has received commitments for a two-tranche placement to existing and new investors to raise approximately $3.5 million at $0.07 per share.
-
Latest News Cyclopharm signs agreement makes major progress with US veterans and defence administrations October 8, 2024Cyclopharm (ASX:CYC) has announced it has entered into an interim agreement to supply the Veterans Health Administration, the most extensive integrated government healthcare system in the US, with the pharmaceutical and consumable components of Technegas.
New Stories
-
More opportunities for connection during Australia's biggest week in biotech
October 17, 2024 - - AusBiotech -
MTPConnect cements US medtech links through MoU with Medical Alley
October 17, 2024 - - Latest News -
Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration
October 17, 2024 - - Latest News -
Anatara Lifesciences provides GaRP-IBS clinical trial update
October 17, 2024 - - Latest News -
Neuren announces that trofinetide has received marketing authorisation in Canada
October 17, 2024 - - Latest News -
Nyrada says it has completed safety studies ahead of Phase 1 clinical trial
October 17, 2024 - - Latest News -
Immuron reports continued sales growth for Travelan
October 15, 2024 - - Latest News